The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics
AbstractMore than 60 years ago, disulfiram (DSF) was employed for the management of alcohol addiction. This promising cancer therapeutic agent inhibits proliferation, migration, and invasion of malignant tumor cells. Furthermore, divalent copper ions can enhance the antitumor effects of DSF. Molecular structure, pharm acokinetics, signaling pathways, mechanisms of action and current clinical results of DSF are summarized here. Additionally, our attention is directed towards the immunomodulatory properties of DSF and we explore novel administration methods that may address the limitations associated with antitumor treatme...
Source: Hormones and Cancer - June 16, 2023 Category: Cancer & Oncology Source Type: research
An immune related signature inhibits the occurrence and development of serous ovarian cancer by affecting the abundance of dendritic cells
In conclusion, an immune related signature with good prediction efficiency was established through systematic bioinformati cs analysis, which may play a tumor inhibition role by affecting the abundance of activated dendritic cells. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 15, 2023 Category: Cancer & Oncology Source Type: research
AURKB activates EMT through PI3K/AKT signaling axis to promote ICC progression
AbstractIntrahepatic cholangiocarcinoma (ICC) is a fatal disease and the molecular mechanism of its progression remains unknown. Aurora Kinase B (AURKB) is a central regulator of chromosome separation and cytokinesis and is abnormally expressed in a variety of cancer cells. This research aimed to explore the effect of AURKB in occurrence and metastasis of ICC. We found that AURKB showed a progressive up-regulation pattern from normal bile duct tissue to ICC with high invasion. Our data showed that AURKB significantly promoted ICC cell proliferation, induced epithelial-mesenchymal transition (EMT), migration and invasion th...
Source: Hormones and Cancer - June 15, 2023 Category: Cancer & Oncology Source Type: research
Modern treatment strategies in pediatric oncology and hematology
AbstractEvery year, approximately 400 00 children worldwide are diagnosed with cancer. Although treatment results in most types of childhood neoplasms are excellent with survival more than 80%, there are some with poor prognosis. Also recurrent and resistant to treatment childhood cancer remain a therapeutic challenge. Besides chemoth erapy, which has been the basis of cancer therapy for years, molecular methods and precisely targeted therapies have recently found their usage. As a result of that, survival has improved and has positively impacted the rate of toxicities associated with chemotherapy (Butler et al. in CA Ca...
Source: Hormones and Cancer - June 14, 2023 Category: Cancer & Oncology Source Type: research
MOB kinase activator 1A acts as an oncogene by targeting PI3K/AKT/mTOR in ovarian cancer
ConclusionsOur findings indicated that MOB1A is highly expressed and related to poor prognosis in OC. MOB1A plays a role in promoting the malignant biological behavior of tumor cells through PI3K/AKT/mTOR signaling pathway. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 14, 2023 Category: Cancer & Oncology Source Type: research
M1A and m7G modification-related genes are potential biomarkers for survival prognosis and for deciphering the tumor immune microenvironment in esophageal squamous cell carcinoma
ConclusionsTranscriptomic prognostic signatures based on m1A and m7G modification-related genes are closely associated with immune cell infiltration in ESCC patients and have important correlations with the therapeutic sensitivity of multiple chemotherapeutic agents. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 14, 2023 Category: Cancer & Oncology Source Type: research
FIBP is a prognostic biomarker and correlated with clinicalpathological characteristics and immune infiltrates in acute myeloid leukemia
AbstractAcute myeloid leukemia (AML) is one of the most common hematological malignancy that has a high recurrence rate. FIBP was reported to be highly expressed in multiple tumor types. However, its expression and role in acute myeloid leukemia remains largely unknown. The aim of this study was to clarify the role and value of FIBP in the diagnosis and prognosis, and to analyze its correlation with immune infiltration in acute myeloid leukemia by The Cancer Genome Atlas (TCGA) dataset. FIBP was highly expressed in AML samples compared to normal samples. The differentially expressed genes were identified between high and l...
Source: Hormones and Cancer - June 13, 2023 Category: Cancer & Oncology Source Type: research
Identification of Piezo1 as a potential target for therapy of colon cancer stem-like cells
In this study, we found that Piezo1 was highly expressed in CD133+/CD44+ colon cancer tissues, and the Piezo1high/CD133+CD44+ population was associated with the clinical stage. Furthermore, CCSCs isolated from colon cell lines expressed higher Piezo1 levels compared to the non-CCSCs, and Piezo1 knockdown inhibited their tumorigenicity and self-renewal capacity. Mechanistically, Piezo1 maintained the stemness of CCSCs through Ca2+/NFAT1 signaling, and knocking down Piezo1 promoted degradation of NFAT1. Taken together, Piezo1 is involved in the stage of colon cancer and is a promising therapeutic target. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 12, 2023 Category: Cancer & Oncology Source Type: research
A demonstration based on multi-omics transcriptome sequencing data revealed disulfidptosis heterogeneity within the tumor microenvironment of esophageal squamous cell carcinoma
ConclusionIn a word, the risk score based on disulfidptosis is associated with prognosis and the immune microenvironment, which may direct immunotherapy of ESCC. The key gene of risk score, namely CD96, plays a role in proliferation and apoptosis in ESCC. We offer an insight into the exploration of the genomic etiology of ESCC for its clinical management. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 12, 2023 Category: Cancer & Oncology Source Type: research
Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers
AbstractBRAF mutant metastatic colorectal cancer has long been considered a tumor with a poor prognosis and a poor response to chemotherapy. Despite the efficacy of targeted therapy with multi-targeted blockade of the mitogen-activated protein kinase (MAPK) signaling pathway has brought a glimmer of hope to this group of patients, the need to improve treatment efficacy remains unmet, especially for the microsatellite stability/DNA proficient mismatch repair (MSS/pMMR) subtype.BRAF mutant colorectal cancer patients with high microsatellite instability/DNA deficient mismatch repair (MSI-H/dMMR) have high tumor mutation burde...
Source: Hormones and Cancer - June 11, 2023 Category: Cancer & Oncology Source Type: research
Possible therapeutic targets for NLRP3 inflammasome-induced breast cancer
AbstractInflammation plays a major role in the development and progression of breast cancer(BC). Proliferation, invasion, angiogenesis, and metastasis are all linked to inflammation and tumorigenesis. Furthermore, tumor microenvironment (TME) inflammation-mediated cytokine releases play a critical role in these processes. By recruiting caspase-1 through an adaptor apoptosis-related spot protein, inflammatory caspases are activated by the triggering of pattern recognition receptors on the surface of immune cells. Toll-like receptors, NOD-like receptors, and melanoma-like receptors are not triggered. It activates the proinfl...
Source: Hormones and Cancer - June 10, 2023 Category: Cancer & Oncology Source Type: research
Adipocyte-derived extracellular vesicles: bridging the communications between obesity and tumor microenvironment
AbstractBy the year 2035 more than 4 billion people might be affected by obesity and being overweight. Adipocyte-derived Extracellular Vesicles (ADEVs/ADEV-singular) are essential for communication between the tumor microenvironment (TME) and obesity, emerging as a prominent mechanism of tumor progression. Adipose tissue (AT) becomes hypertrophic and hyperplastic in an obese state resulting in insulin resistance in the body. This modifies the energy supply to tumor cells and simultaneously stimulates the production of pro-inflammatory adipokines. In addition, obese AT has a dysregulated cargo content of discharged ADEVs, l...
Source: Hormones and Cancer - June 8, 2023 Category: Cancer & Oncology Source Type: research
AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research
ConclusionsThe anticancer effect of the drug combination was confirmed to be better than monotherapy in vitro and in vivo. The results of this study may provide some information for the plan of neoadjuvant therapy and the design of clinical trials for lung adenocarcinoma patients with KRAS G12C mutation. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 7, 2023 Category: Cancer & Oncology Source Type: research
Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)
ConclusionsAlthough the metformin plus temozolomide regimen was well tolerated, it did not confer a clinical benefit in patients with recurrent or refractory GBM.Trial registration NCT03243851, registered August 4, 2017. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 6, 2023 Category: Cancer & Oncology Source Type: research
ABHD17C, a metabolic and immune-related gene signature, predicts prognosis and anti-PD1 therapy response in pancreatic cancer
ConclusionTherefore, ABHD17C may be a novel and effective biomarker for predicting the metabolic status and immune condition of PDAC patients, and provide a potential predictive strategy for anti-PD1 therapy in PDAC. (Source: Hormones and Cancer)
Source: Hormones and Cancer - June 5, 2023 Category: Cancer & Oncology Source Type: research
